Table 1 Baseline characteristics according to endocrine resistance in patients who received adjuvant endocrine therapy.
Primary endocrine resistance (N = 28) | Secondary endocrine resistance (N = 46) | Endocrine Sensitive (N = 24) | Total (N = 98) | P value | |
|---|---|---|---|---|---|
Age (median, range) | 45 (28–77) | 44 (30–74) | 48 (23–75) | 45 (23–77) | 0.973 |
Histologic type | 0.789a | ||||
IDC | 23 (82.1%) | 42 (91.3%) | 21 (87.5%) | 86 (87.8%) | |
ILC | 2 (7.1%) | 2 (4.3%) | 1 (4.2%) | 5 (5.1%) | |
Others | 3 (10.7%) | 2 (4.3%) | 2 (8.3%) | 7 (7.1%) | |
HGb | 0.493a | ||||
1 or 2 | 21 (84.0%) | 37 (86.0%) | 21 (95.5%) | 79 (87.8%) | |
3 | 4 (16.0%) | 6 (14.0%) | 1 (4.5%) | 11 (12.2%) | |
LVIb | 0.316 | ||||
No | 14 (66.7%) | 27 (73.0%) | 12 (92.3%) | 53 (74.6%) | |
Yes | 7 (33.3%) | 10 (27.0%) | 1 (7.7%) | 18 (25.4%) | |
T stage | 0.011a | ||||
1 | 8 (28.6%) | 23 (50.0%) | 13 (54.2%) | 44 (44.9%) | |
2 | 15 (53.6%) | 23 (50.0%) | 11 (45.8%) | 49 (50.0%) | |
3 | 5 (17.9%) | 0 | 0 | 5 (5.1%) | |
N stage | 0.336a | ||||
0 | 11 (39.3%) | 20 (43.5%) | 11 (45.8%) | 42 (42.9%) | |
1 | 8 (28.6%) | 16 (34.8%) | 9 (37.5%) | 33 (33.7%) | |
2 | 3 (10.7%) | 4 (8.7%) | 4 (16.7%) | 11 (11.2%) | |
3 | 6 (21.4%) | 6 (13.0%) | 0 | 12 (12.2%) | |
Stage | 0.424 | ||||
1 | 6 (21.4%) | 14 (30.4%) | 10 (41.7%) | 30 (30.6%) | |
2 | 12 (42.9%) | 22 (47.8%) | 10 (41.7%) | 44 (44.9%) | |
3 | 10 (35.7%) | 10 (21.7%) | 4 (16.7%) | 24 (24.5%) | |
Breast surgery | 0.083 | ||||
BCS | 6 (21.4%) | 18 (39.1%) | 12 (50.0%) | 36 (36.7%) | |
TM | 22 (78.6%) | 28 (60.9%) | 12 (50.0%) | 62 (63.3%) | |
Axillary surgery | 0.142 | ||||
SLNB | 9 (26.5%) | 8 (17.4%) | 9 (37.5%) | 26 (26.5%) | |
ALND | 19 (67.9%) | 38 (82.6%) | 15 (62.5%) | 72 (73.5%) | |
Adjuvant chemotherapy | 0.426 | ||||
No | 4 (14.3%) | 10 (21.7%) | 7 (29.2%) | 21 (21.4%) | |
Yes | 24 (85.7%) | 36 (78.3%) | 17 (70.8%) | 77 (78.6%) | |
Adjuvant endocrine | 0.466 | ||||
Tamoxifen | 17 (60.7%) | 30 (65.2%) | 12 (50.0%) | 59 (60.2%) | |
AI | 11 (39.3%) | 16 (34.8%) | 12 (50.0%) | 39 (39.8%) | |
Adjuvant radiotherapy | 0.402 | ||||
No | 8 (28.6%) | 20 (43.5%) | 8 (33.3%) | 36 (36.7%) | |
Yes | 20 (71.4%) | 26 (56.5%) | 16 (66.7%) | 62 (63.3%) |
